I. Chang

发表

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

P. Ascierto, J. Larkin, A. Ribas, 2014, The New England journal of medicine.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Tae Won Kim, N. Segal, M. Fakih, 2019, The Lancet. Oncology.

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

C. Rudin, M. Borad, P. LoRusso, 2011, Clinical Cancer Research.

Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.

P. Ascierto, J. Larkin, J. Sosman, 2018, JCO precision oncology.

A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry

I. Chang, C. Hop, Y. Shin, 2011, Drug Metabolism and Disposition.

Daily Dosing of Vismodegib to Steady State Does Not Prolong the Qtc Interval in Healthy Volunteers

I. Chang, J. Low, R. Graham, 2013, Journal of cardiovascular pharmacology.

P. Ascierto, J. Larkin, A. Ribas, 2018, British Journal of Cancer.

Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors

J. Berlin, A. Jimeno, P. LoRusso, 2011, Clinical Cancer Research.

The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.

P. van Hoek, A. Cleton, I. Chang, 2009, Pharmacopsychiatry.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Matthew Wongchenko, Paolo A Ascierto, Antoni Ribas, 2016, The Lancet. Oncology.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

P. Ascierto, J. Larkin, J. Sosman, 2019, Clinical Cancer Research.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission

B. Karlan, P. Sabbatini, L. Fehrenbacher, 2012, Clinical Cancer Research.

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Sandra M. Sanabria-Bohórquez, G. Shapiro, P. LoRusso, 2020, Investigational New Drugs.

Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.

J. Schellens, J. Beijnen, W. S. Siegel-Lakhai, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

A. Hauschild, K. Flaherty, P. Ascierto, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

results from a randomised, double-blind, phase 3 trial

P. Ascierto, J. Larkin, A. Ribas, 2016 .

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.

M. Borin, I. Chang, C. Hop, 2012, British journal of clinical pharmacology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma.

P. Ascierto, J. Larkin, A. Ribas, 2015 .

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

P. Hegde, P. Ascierto, J. Larkin, 2017, Clinical Cancer Research.

The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics

A. Ribas, A. Joe, G. Daniels, 2014, Journal of clinical pharmacology.

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

S. Dejager, V. Fonseca, I. Chang, 2007, Diabetologia.

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

P. Ascierto, J. Larkin, A. Ribas, 2015, Journal of Translational Medicine.

Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics

S. Girish, I. Chang, N. Choong, 2020, Clinical pharmacology in drug development.

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.

J. Tabernero, N. Segal, M. Fakih, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract B75: A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.

A. El-Khoueiry, J. Bendell, I. Chang, 2013 .

Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors

G. Shapiro, P. LoRusso, J. Bendell, 2014 .

Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C).

P. Ascierto, J. Larkin, A. Ribas, 2015 .

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer

P. Hegde, J. von Pawel, E. Juhász, 2018, The oncologist.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.

P. Ascierto, J. Larkin, A. Ribas, 2018, JCO precision oncology.

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

P. Ascierto, J. Larkin, J. Sosman, 2016 .

Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).

P. Ascierto, J. Larkin, A. Ribas, 2016 .

P. Ascierto, J. Larkin, A. Ribas, 2015, Journal of Translational Medicine.

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The Oncologist.

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer

P. Hegde, J. von Pawel, E. Juhász, 2018, The oncologist.

A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.

P. Hegde, P. Munster, L. Naumovski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.